Milestone Pharmaceuticals Inc.
MIST · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.07 | -0.41 | -0.09 | 0.16 |
| FCF Yield | -19.67% | -64.87% | -31.37% | -12.13% |
| EV / EBITDA | -4.19 | -1.93 | -2.79 | -3.74 |
| Quality | ||||
| ROIC | -61.58% | -89.13% | -86.02% | -37.94% |
| Gross Margin | 0.00% | 100.00% | 90.40% | 100.00% |
| Cash Conversion Ratio | 0.69 | 0.78 | 0.90 | 0.78 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -59.45% | – | – |
| Free Cash Flow Growth | 37.94% | 11.77% | -58.74% | 34.51% |
| Safety | ||||
| Net Debt / EBITDA | -0.70 | -0.67 | 0.09 | 2.64 |
| Interest Coverage | 11.76 | -23.92 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | -1.45 | 0.00 |
| Cash Conversion Cycle | -1,091.61 | 1,405.62 | -1,883.97 | 11.75 |